A Study of Muscle Strength Maintenance in Older Adults

Completed · Phase 2 · Has a placebo group

Conditions studied: Sarcopenia

In brief

This research study is being done to see whether losartan can prevent the decrease in strength associated with aging. Muscle loss is associated with aging and has multiple symptoms such as weakness, slowness, and fatigue (tiredness). Older adults with muscle weakness have a higher risk of falls and disability. In addition, the loss of independence for older adults can lead to a poorer quality of life. Recently, it was discovered that losartan, a medication commonly used to treat high blood pressure, had slowed the strength decline seen in older mice. In addition, it allowed injured mice skeletal muscle to heal faster. Therefore, we would like to see if losartan can do the same for older adults. Losartan is approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure, heart failure, and to protect the kidneys in diabetic patients. Losartan is not FDA-approved to prevent the decrease in strength associated with aging. In this study, participants age 70 and older will be asked to take losartan or a placebo to see if losartan can help prevent loss of muscle strength. A placebo is a substance that looks like the study drug but that contains no active ingredients.

Key facts

Study ID

NCT01989793

Run by

Johns Hopkins University

People needed

37

Starts

2013-07-01

Expected to finish

2016-10-01

Last updated by the study team

2018-06-12

Who can join

Age: 70 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 70 and over
• Pre-frail as determined by frailty criteria

You may not qualify if…

• Under age 70
• Robust or frail by frailty criteria
• Have other indications for use of any angiotensin-receptor blockers (ARB) such as myocardial infarction in past year, history of congestive heart failure, uncontrolled hypertension
• Current use of ARBs or angiotensin-converting enzyme (ACE) inhibitors
• Prior allergic reaction to or hyperkalemia with losartan or any ARB
• Chronic renal failure with a glomerular filtration rate of < 30
• Current daily use of non-steroidal anti-inflammatory agents
• Current use of steroids
• Lower extremity disability that would prevent muscle strength testing
• Echocardiogram-diagnosed cardiac failure as evidenced by left ventricular ejection fraction less than 50%
• Cognitive impairment with a Mini-Mental State Examination < 24

Where it is running

• Johns Hopkins Bayview Clinical Research Unit — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.